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Abstract
Background: Angiodysplasias are one of the most frequent causes of gastrointestinal bleed-
ing. Pharmacological options, such as octreotide Long-Acting Release (LAR), do not yet have a
deﬁned role and are currently used for patients who are not candidates for or are refractory to
endoscopic treatment.
Aims: (1) To evaluate the efﬁcacy of octreotide LAR by considering transfusion requirements
(units of packed erythrocytes (UPE)/month) and number of hospitalizations/month before and
during therapy; (2) to verify whether the characteristics of patients and/or concurrent medi-
cation inﬂuenced response to therapy; and (3) to evaluate the safety of therapy by registering
adverse effects.
Methods: A retrospective cohort of 16 patients with angiodysplasias treated with octreotide
LAR was reviewed.
Results: (1) There was a signiﬁcant decrease (follow up before vs. follow up during) in the
median number of UPE/month (1.84 vs. 0.42, p = 0.008) and the number of admissions/month
(0.21 vs. 0.00, p = 0.015). (2) Of the characteristics analyzed, only the presence of aortic steno-
sis (vs. other comorbidities) positively inﬂuenced the response to therapy in relation to the
variation in transfusion requirements (−2.39UPE/month vs. −0.61UPE/month; p = 0.009). (3)
Adverse effects: splenic infarction (1 patient) and gallstones (1 patient).
Conclusions: Octreotide LAR is effective as prophylaxis for gastrointestinal bleeding angiodys-
plasia by decreasing transfusion requirements and the need for hospitalizations. Patients with
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aortic stenosis were those who most beneﬁted from the therapy. A dose of 20mg/month did
not prove more effective than a dose of 10mg/month.
© 2013 Sociedade Portuguesa de Gastrenterologia. Published by Elsevier España, S.L.U. All rights
reserved.
PALAVRAS-CHAVE
Octreótido
Long-Acting Release;
Angiodisplasias;
Hemorragia Digestiva
O octreótido Long-Acting Release é eﬁcaz na prevenc¸ão de hemorragia por
angiodisplasias gastrointestinais
Resumo
Introduc¸ão: As angiodisplasias são uma das causas mais frequentes de hemorragia com ponto
de partida no intestino delgado. As opc¸ões farmacológicas como o octreótido LAR não têm
ainda um papel deﬁnido destinando-se a doentes não candidatos ou refratários à terapêutica
endoscópica.
Objetivos: (1) Avaliar a eﬁcácia terapêutica comparando: necessidades transfusionais (unidades
de concentrado eritrocitário/mês) e número de internamentos/mês antes e durante a terapêu-
tica; (2) Veriﬁcar se as características dos doentes e/ou da medicac¸ão tiveram inﬂuência na
resposta à terapêutica; (3) Avaliar a seguranc¸a da terapêutica (registo de efeitos adversos).
Métodos: Efetuado estudo retrospetivo de coorte de 16 doentes com AD tratados com octreótido
LAR.
Resultados: (1) Observou-se diminuic¸ão signiﬁcativa (follow up before vs follow up during) do
número mediano de UCE/mês [1.84 UCE/mês vs 0,42 UCE/mês; p=0.008] e do número de
internamentos/mês [0,21 internamentos/mês vs 0,00 internamentos/mês; p=0.015]. (2) Das
características analisadas, apenas a presenc¸a de estenose aórtica (vs outras comorbilidades)
inﬂuenciou positivamente a resposta à terapêutica no que concerne à variac¸ão das necessi-
dades transfusionais (--2,39 UCE/mês vs --0,61 UCE/mês; p=0,009). (3) Efeitos adversos: enfarte
esplénico (1 doente); litíase vesicular (1 doente).
Conclusão: O octreótido LAR é eﬁcaz como proﬁlaxia de hemorragia por angiodisplasias gas-
trointestinais diminuindo as necessidades transfusionais e a necessidade de internamentos. Os
doentes com estenose aórtica foram aqueles que mais beneﬁciaram com a terapêutica. A dose
de 20mg/mês não provou ser mais eﬁcaz que a dose de 10mg/mês.
© 2013 Sociedade Portuguesa de Gastrenterologia. Publicado por Elsevier España, S.L.U. Todos
os direitos reservados.
b
c
i
p
h
b
w
s
d
o
e
t
o
aIntroduction
Angiodysplasias are the major vascular malformations of the
digestive tract and are the most frequent cause of gastroin-
testinal bleeding originating in the small bowel in individuals
over 50 years of age.1
The pathogenesis of angiodysplasias is unclear, although
they are presumed to result from degenerative processes,
neurohormonal dysfunction or complications of an under-
lying disease, such as chronic kidney failure (CKF), liver
cirrhosis or aortic stenosis.1
About 40--60% of the patients have multiple
angiodysplasias2,3 and, while most patients have vascular
malformations in the same intestinal segment, synchronous
lesions can be identiﬁed elsewhere in the gastrointestinal
tract in approximately 20% of the patients.4,5
Diagnosis can be challenging, mainly because bleeding
is intermittent or patients are anaemic or with hypotension
which makes angiodysplasias less obvious on light endoscopy.
In addition to this, angiodysplasias in the small bowel are
relatively difﬁcult to access by endoscopy, although this has
p
a
c
seen aided by the introduction and widespread use of video
apsule enteroscopy (VCE) and balloon-assisted enteroscopy
n clinical practice.
The aims of the treatment of gastrointestinal angiodys-
lasias are, ﬁrstly, the cessation of acute or chronic
aemorrhage and, secondly, the prevention of recurrence of
leeding. Besides the correction of the underlying disease,
hen applicable, this treatment is aided by blood transfu-
ion and correction of any coagulation disorders and/or the
iscontinuation of antiplatelet therapy or anticoagulants.1,6
The commitment of the clinician to avoid the recurrence
f bleeding from angiodysplasias should be guided by knowl-
dge of the natural history of this disease and the notion
hat about 50% of the patients relapse after a ﬁrst episode
f haemorrhage.6
The potentially most effective therapeutic interventions
re: endoscopy (especially the destruction of angiodys-
7lasias with argon plasma coagulation) ; therapeutic
ngiography (super-selective embolization) especially in the
ontext of acute haemorrhage8 and surgery (in patients
elected on the basis of clinical presentation, location of
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he lesions and the patient’s age and comorbidities).9 When
hese interventions are not possible, are contraindicated or
ave been ineffective, as often happens in patients with
ultiple lesions distributed across several segments of the
igestive tract or when the patient has comorbidities that
revent performing invasive procedures, pharmacological
reatment is the only alternative possibility.6,10
Various drugs have been reported, commonly in clin-
cal case studies, to be beneﬁcial in the treatment of
astrointestinal bleeding from angiodysplasias. The three
ost promising drugs for this indication are hormonal ther-
py with a combination of oestrogen--progesterone,11--16
ctreotide17--21 and thalidomide.22,23
The objectives of our study were: (1) to determine the
ffectiveness of therapy with octreotide LAR in patients with
ecurrent episodes of gastrointestinal bleeding as a result
f gastrointestinal angiodysplasia, assessing the need for
ransfusion and the number of hospitalizations for gastroin-
estinal bleeding by comparing periods before and during
herapy, (2) to verify whether the characteristics of patients
nd/or the concurrent medication had an inﬂuence on the
esponse to therapy, and (3) to evaluate the safety of this
herapy (adverse effects).
atients and methods
e retrospectively evaluated all patients followed in our
ospital between 2003 and 2011 with recurrent episodes
f gastrointestinal bleeding originating from gastrointestinal
ngiodysplasias characterized by iron-deﬁciency anaemia or
vert gastrointestinal bleeding episodes in which angiodys-
lasias were observed by endoscopy and all other possible
auses of gastrointestinal bleeding were excluded.
All patients included in the study underwent colonoscopy,
ndoscopy and VCE. Some patients also underwent double-
alloon enteroscopy (examination always of therapeutic
urpose).
Whenever feasible, endoscopic therapy was performed
ith argon plasma coagulation. When, despite endoscopic
reatment, patients had recurrent bleeding (deﬁned as
t least two episodes of gastrointestinal bleeding from
ngiodysplasias for a period of 6 months) or were not
andidates for endoscopic treatment (due to multiple
ngiodysplasias dispersed through the digestive tract or due
o contraindications to invasive procedures) they were ini-
iated onto therapy with octreotide LAR (Sandostatin LAR,
ovartis Pharma®).
Since the dose of this drug has varied between studies and
ecause comparative studies are lacking, the dosage used
10 or 20mg monthly octreotide LAR, intramuscular) was
hosen according to the decision of the physician responsible
or the patient (without taking into account any objective
riteria such as age, weight, severity of the disease, number
f blood transfusions or number of hospitalizations driven by
astrointestinal bleeding).
Blood transfusions were performed whenever the
aemoglobin value fell below 7.5 g/dL (for any patient) or
elow 10 g/dL (in patients with ischaemic heart disease).
The follow-up period from the date of diagnosis of
ngiodysplasias haemorrhage to the start time of treatment
ith octreotide LAR was called ‘‘follow up before’’ and the
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ime during which the patient received therapy was called
‘follow up during’’.
Patients were monitored clinically and analytically dur-
ng the periods of follow-up by registering sex, age, location
f angiodysplasias, whether or not an endoscopic treatment
as performed, comorbidities associated with the presence
f angiodysplasias (aortic stenosis, CKF and liver cirrhosis),
oncomitant medications (antiplatelets or hipocoagulants),
umber of hospitalizations (motivated by gastrointestinal
leeding), number of blood transfusions performed and
dverse effects during therapy.
As the times ‘‘follow up before’’ and ‘‘follow up during’’
aried from patient to patient, the average monthly trans-
usion rate (units of packed erythrocytes (UPE)/month) and
he average number of hospitalizations per month (num-
er of visits divided by the number of months of follow
p) were used. To verify whether the characteristics of
atients and/or concurrent medications inﬂuenced response
o therapy, we compared the variations in average trans-
usion rate (difference between the average UPE/month
uring ‘‘follow up during’’ and ‘‘follow up before’’) and
he number of admissions per month (the average differ-
nce between inpatient admissions/month during ‘‘follow
p during’’ and ‘‘follow up before’’) isolating each variable
ndependently.
In the descriptive analysis of the variables we used the
elative frequencies for dichotomous variables, measures of
entral tendency and dispersion for continuous variables.
To compare whether there was a difference between the
alues of continuous variables assessed at two points in time
before and during) we used the nonparametric Wilcoxon
igned rank test.
When comparing quantitative variables from two inde-
endent groups we used the nonparametric Mann--Whitney
test.
To analyze the association between two qualitative varia-
les we used the Fisher’s exact test.
Statistical tests were performed bilaterally considering a
igniﬁcance level of 5%.
The statistical analysis was performed on IBM SPSS Statis-
ics 20.0 software.
esults
ixteen patients were included in this study, nine were
emale (56.3%) and seven were male (43.8%) patients.
edian age was 68.5 years (range: 48--81).
All patients had multiple vascular lesions and the most
ommon location of these was the small bowel (n = 12; 75%).
ix patients (37.5%) had angiodysplasias in multiple loca-
ions.
Endoscopic treatment with argon plasma coagulation was
requently performed (n = 9; 56.25%) and some patients were
ubjected to several sessions of endoscopic therapy.
Only 1 patient showed no evidence of comorbidity asso-
iated with angiodysplasias. Some patients had more than
ne comorbidity: CKF, n = 7 (43.75%); aortic stenosis, n = 6
37.5%); cirrhosis, n = 5 (31.25%).
Concomitant medication (anticoagulation/antiplatelet
herapy) was very common, reﬂecting the multiple comor-
idities present in this cohort of patients: ﬁve patients
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Table 1 Clinical and demographic data.
Patient Gender Age Localization
of angiodys-
plasias
Endoscopic
therapy
Comorbidities Anticoagulation
therapy
Antiaggregation
therapy
1 F 79 Stomach;
small bowel
Yes Aortic
stenosis
-- Acetylsalicylic
acid
2 F 63 Small bowel -- CKF Acenocoumarol --
3 F 60 Stomach;
colon
Yes Cirrhosis;
CKF
-- --
4 M 60 Small bowel Yes -- -- --
5 M 68 Stomach Yes Cirrhosis;
CKF
-- --
6 F 69 Small bowel -- Aortic
stenosis
Acenocoumarol Acetylsalicylic
acid
7 F 55 Small bowel -- Aortic
stenosis
Acenocoumarol --
8 F 73 Small bowel Yes Cirrhosis Acenocoumarol --
9 M 81 Stomach Yes CKF -- Acetylsalicylic
acid
10 F 48 Small bowel -- CKF -- --
11 M 80 Small
bowel;
colon
-- Aortic
stenosis
-- Clopidogrel
12 M 70 Colon -- CKF -- --
13 F 70 Stomach;
small bowel
Yes Aortic
stenosis
Warfarin Acetylsalicylic
acid
14 M 55 Stomach;
small bowel
Yes Cirrhosis;
CKF
-- --
15 M 65 Small bowel -- Cirrhosis -- --
16 F 77 Small
bowel;
colon
Yes Aortic
stenosis
-- Acetylsalicylic
acid
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tF, female; M, male; CKF, chronic kidney failure.
(31.25%) were on anti-coagulation therapy and six (37.5%)
were on anti-aggregation therapy.
Table 1 summarizes the clinical and demographic charac-
teristics of the included patients.
The median follow-up before the start of octreotide LAR
was 14 months (range: 10--20) and patients remained on
treatment with this drug (‘‘follow up during’’) for a median
time of 12 months (range: 7--24).
The dosages used were 10mg/month and 20mg/month
in 9 patients (56.25%) and 7 patients (43.75%) respectively.
In the period of ‘‘follow up before’’ 5.26UPE were
transfused on average (range: 10--47), which corresponds
to an average transfusion rate of 1.93UPE per month
(median: 1.84UPE/month) and patients were admitted for
gastrointestinal bleeding on average 2.9 times (range: 0--6),
corresponding to a median of 0.21 hospitalizations per
month. In the period of ‘‘follow up during’’ 7.63UPE were
transfused on average (range: 0--46), corresponding to an
average transfusion rate of 0.65UPE per month (median:
0.42UPE/month) and there were on average 0.94 admissions
(range: 0--4) corresponding to a median of 0.00 hospitaliza-
tions per month.
Table 2 summarizes the data for the periods of follow-up,
including transfusion requirements, hospitalization, doses
and adverse effects.
(
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wConsidering rates of transfusion (Table 3), there was a sig-
iﬁcant decrease in the median UPE/month in the ‘‘follow
p before’’ period compared to the ‘‘follow up during’’
eriod (1.84UPE/month vs. 0.42UPE/month; p = 0.008).
hen comparing the number of admissions per month
etween these two periods (Table 3), there was also a sta-
istically signiﬁcant decrease (0.21 hospitalizations/month
s. 0.00 admissions/month; p = 0.015).
When considering the variation in the transfusion rate
nd average number of hospitalizations per month in the
eriods ‘‘follow up before’’ and ‘‘follow up during’’,
ndependently isolating each variable studied (univariate
nalysis), we observed that only the presence of aortic
tenosis positively inﬂuenced the response to therapy in
erms of reduced transfusion requirements compared with
atients with other comorbidities (−2.39UCE/month vs.
0.61UCE/month, p = 0.009). No other characteristic ana-
yzed affected the response to therapy including octreotide
ose (Table 4). There were no clinical differences between
he group of patients treated with 10mg/month vs. those
reated with 20mg/month (Table 5).Adverse effects occurred in two of the patients studied
gallstones and splenic infarction). In the patient develop-
ng splenic infarction, medication was discontinued. There
as no association between the dosage of octreotide
180 P. Salgueiro et al.
Table 2 Data on follow up, transfusion requirements, hospital admissions, dosage and adverse events of octreotide.
Patient Follow up
before
(months)
Follow up
during
(months)
Number of
UPE (follow
up before)
Number of
UPE (follow
up during)
Hospital
admissions
(follow up
before)
Hospital
admissions
(follow up
during)
Dose
(mg/month)
Adverse effects
1 20 24 47 10 3 3 20 --
2 13 12 17 2 2 0 10 --
3 14 10 11 13 4 2 10 --
4 17 10 12 0 2 0 10 --
5 10 14 23 6 6 0 20 --
6 17 13 31 2 0 0 10 --
7 14 14 26 2 3 1 10 --
8 15 7 20 11 4 3 20 Splenic infarction
9 20 12 36 46 4 4 20 --
10 15 13 30 9 3 1 10 --
11 11 10 35 0 3 0 20 --
12 12 12 10 0 3 0 10 --
13 10 12 21 2 3 1 20 Gallstones
14 17 14 43 8 2 0 10 --
15 12 12 18 5 1 0 20 --
16 10 12 44 6 4 0 10 --
Table 3 Comparison of average transfusion rates and the average number of admissions per month between ‘‘follow up before’’
and ‘‘follow up during’’.
Mean Median pa
UPE/month (‘‘follow up before’’) 1.93 1.84
UPE/month (‘‘follow up during’’) 0.65 0.42 p = 0.008
Admissions/month (‘‘follow up before’’) 0.23 0.21
Admissions/month (‘‘follow up during’’) 0.08 0.00 p = 0.015
a Wilcoxon test.
Table 4 Comparison of changes in average transfusion rate and the average number of admissions per month between periods
of ‘‘follow up during’’ and ‘‘follow up before’’ independently isolating each of the characteristics of patients and medication.
UPE/month (difference during -- before) Admissions/month (difference during -- before)
Mean (UPE/month) pa Mean (admissions/month) pa
Dose
10mg/month vs.
20mg/month
−1.41 vs. −1.10 0.874 −0.15 vs. − 0.13 0.560
Comorbidity
Aortic stenosis vs. other −2.39 vs. −0.61 0.009 −0.18 vs. −0.12 0.447
Cirrhosis vs. other −0.83 vs. −1.48 0.461 −0.14 vs. −0.14 0.427
CKD vs. other −0.31 vs. −1.60 0.115 −0.10 vs. −0.16 0.903
Hipocoagulation therapy
Yes vs. no −1.24 vs. −1.29 0.910 −0.07 vs. −0.18 0.533
Antiaggregation therapy
Yes vs. no −1.79 vs. −0.99 0.103 −0.13 vs. −0.15 0.914
Endoscopic treatment
Yes vs. no −1.06 vs. −1.56 0.958 −0.14 vs. −0.15 0.560a Mann--Whitney test.
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Table 5 Clinical differences between the group of patients treated with 10mg/month vs. those treated with 20mg/month.
10mg/month (n = 9) 20mg/month (n = 7)
Age (mean) 61.9 73.7 p = 0.08a
Endoscopic therapy (%) 44.4 71.4 p = 0.358b
Aortic stenosis (%) 33.3 42.9 p = 1.0b
Anticoagulation therapy (%) 33.3 28.6 p = 1.0b
Antiaggregation therapy (%) 22.2 44.4 p = 0.302b
Number of UPE before therapy (mean) 1.8 2.1 p = 0.315a
Number of UPE during therapy (mean) 0.4 0.9 p = 0.457a
Hospital admissions before therapy (mean) 2.6 3.4 p = 0.227a
Hospital admissions during therapy (mean) 0.4 1.6 p = 0.178a
a Mann--Whitney test.
b Fisher’s test.
Table 6 Comparison between the dose and the occurrence
of adverse events.
Adverse effects (n) Total
No Yes
Dose
10mg/month 9 0
20mg/month 5 2
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Fisher’s exact test: p = 0.175.
LAR and the occurrence of adverse events (p = 0.175)
(Table 6).
Discussion
The drugs used as prophylaxis for haemorrhage due to
gastrointestinal angiodysplasias with the greatest emphasis
within the literature are oestrogen--progesterone, thalido-
mide and octreotide.
The efﬁcacy of oestrogen--progesterone in preventing the
recurrent haemorrhage of gastrointestinal angiodysplasias
continues to be controversial.6,11 Although the mechanisms
of action are not fully understood, the proposed effects
of hormone therapy include restoration of endothelial
integrity, procoagulant effects and stasis effect on mesen-
teric microcirculation.24--26 These effects are not immediate
and they appear to be dependent on the dose of oestro-
gen (usually 10--60 micrograms/day of ethinylestradiol).27
Conﬂicting results were obtained in studies investigating
the efﬁcacy of this therapy for this indication, with sig-
niﬁcant differences in the methodology used in several
published studies (different types of patients, doses and for-
mulations of oestrogen--progesterone).12,28,29 In the largest
prospective, randomized and controlled trial to date, which
included 72 patients, Junquera et al.16 showed that hor-
mone therapy was ineffective in preventing rebleeding or
decreasing transfusion requirements. In this study, there was
rebleeding or recurrent iron deﬁciency anaemia in 39% of
the treated patients vs. 46% of the patients in the placebo
group, after a follow-up period of 1--2 years (difference not
signiﬁcant). There are, however, important limitations of
a
b
t
ahis study, such as the use of low doses of ethinylestra-
iol, errors in the analysis and stratiﬁcation of patients
patients analyzed interchangeably with acute and chronic
on-bleeding and haemorrhage by considering separately
he angiodysplasias affecting the small bowel) and the exclu-
ion of patients with angiodysplasias associated with liver
irrhosis and Rendu--Osler--Weber syndrome (subgroups that
ould possibly beneﬁt more from this therapy6). In addi-
ion, the patients included in this study generally showed
ild disease and had not received prior or concurrent endo-
copic treatment.6,11,27 Thus, these discouraging results may
ot be applicable to all patients. Although hormone therapy
s low cost and may possibly have major beneﬁts in cer-
ain subgroups of patients,11 the efﬁcacy and safety of other
gents may place hormone therapy as a second-line therapy
r adjunctive therapy in some cases.
The gastrointestinal angiodysplasias seem to be associ-
ted with increased serum levels of vascular endothelial
rowth factor (VEGF), this being touted as a possible eti-
logic factor of this important entity. High concentrations
f VEGF are associated with aberrant angiogenesis and the
ormation of angiodysplasias lesions with a thinner muscle
ayer, which causes high vascular fragility and a tendency
o haemorrhage.22 Thalidomide inhibits VEGF, which is the
ationale for its use for this indication. Recently, Zhi-Zheng
e et al.23 showed in a prospective randomized study involv-
ng 28 patients treated with thalidomide (100mg daily
O for 4 months) and control patients treated only with
ron, a signiﬁcant reduction of bleeding episodes (response
ates in thalidomide-treated group and the control group of
1.4% and 3.7% respectively) during the ﬁrst year of follow-
p. In this study there was also a signiﬁcant decrease in
erum levels of VEGF in the group of patients on therapy
ith thalidomide. There were no serious adverse effects
lthough minor adverse effects were frequently observed
ithin the therapeutic group. Thus, probably by decreasing
he concentration of VEGF, thalidomide may be an effective
herapeutic option that is relatively safe in patients with
astrointestinal bleeding angiodysplasias.
Octreotide is a synthetic octapeptide analogue of
omatostatin with similar pharmacologic effects, but with
considerably longer half-life. The proposed mechanisms
y which somatostatin analogues can act to decrease gas-
rointestinal haemorrhage resulting from angiodysplasias
re: inhibition of angiogenesis, splanchnic vasoconstriction,
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ncreased vascular resistance and increased platelet
ggregation.17 In the largest series published to date,18 32
on-cirrhotic patients with diagnosis of intestinal bleeding
econdary to angiodysplasias were treated with octreotide
t a dose of 50 micrograms subcutaneously (twice a day) for
period of 1--2 years. In the present cohort, patients treated
ith octreotide had a lower frequency of recurrent bleed-
ng compared to those who received placebo (23% vs. 48%);
oreover, treatment with octreotide reduced the need for
urther treatment with iron.
The requirement for long-term daily subcutaneous
dministrations is a disadvantage of treatment with
ctreotide. To overcome this, a sustained-release formula-
ion (Octreotide LAR), requiring only monthly intramuscular
dministration, was developed maintaining the same safety
roﬁle and efﬁcacy of subcutaneous octreotide in the treat-
ent of diseases such as acromegaly and neuro-endocrine
umours.30,31
Octreotide LAR was tested in the treatment of chronic
leeding secondary to gastrointestinal angiodysplasias in a
mall series of 3 patients,19 wherein the authors reported
signiﬁcant decrease in the number of hospitalizations and
lood transfusions and an increase in average haemoglobin
fter initiation of octreotide LAR treatment (20mg/month)
uring a follow-up period of 15--17 months. In another ret-
ospective study, including 13 patients treated for one year
ith 10mg octreotide LAR per month,20 nine patients did
ot require blood transfusions or iron supplementation dur-
ng the observation period (12--60 months). More recently,
on et al.21 published a study including 15 patients with
ngiodysplasias treated with octreotide LAR for a median
ime of 12 months (range: 6--36). The authors observed
decrease in the transfusion requirements [median: 10
range: 6--24) vs. 2 (range: 0--14), p < 0.001] and the
roportion of patients experiencing new episodes of gas-
rointestinal bleeding (20% vs. 73%, p = 0.01), on comparing
he period before therapy with the period during therapy.
n this study the mean haemoglobin level increased dur-
ng the period in which patients received treatment with
ctreotide LAR [median: 7 (range: 5--8.5) vs. 10 g/dl (range:
--13), p < 0.001].
Similarly, in our study, this therapy was effective in
educing the need for transfusion and hospitalization when
omparing the periods ‘‘follow up before’’ and ‘‘follow up
uring’’. We note that, in our study, the transfusion needs of
hree patients were reduced to zero (patients 4, 11 and 12)
nd eight patients (patients 2, 4, 5, 11, 12, 14, 15 and 16) no
onger needed to be hospitalized for gastrointestinal bleed-
ng after the initiation of treatment. Only two patients failed
o respond to therapy, and these patients actually increased
heir requirement for transfusion (patients 3 and 9). In one
f these patients (patient 3), poor compliance to treatment
otentially accounts for this lack of response, although the
eason behind the lack of response in the other case (patient
) is unknown.
A comparison of patient characteristics revealed that the
resence of valvular heart disease (aortic stenosis) was the
nly factor positively inﬂuencing the response to therapy.
n patients with aortic stenosis, turbulent passage of blood
hrough the stenosed valve results in mechanical disrup-
ion of vonWillebrand factor multimers, which causes the
evelopment of an acquired form of vonWillebrand’s diseaseP. Salgueiro et al.
Heyde’s syndrome).32 Octreotide, by improving platelet
ggregation,17 directly rectiﬁes the mechanism by which
ortic stenosis leads to increased bleeding episodes by diges-
ive angiodysplasias, and this may be the explanation for the
est response to therapy of these patients in our series.
Additionally, for the ﬁrst time, we compared two
oses of octreotide LAR and we found that higher doses
20mg/month) did not translate to therapeutic beneﬁt. The
esponse to this drug depends upon the binding of octreotide
o several receptor subtypes. The somatostatin receptor
ubtype 2 binds octreotide with the greatest afﬁnity, and
his receptor is expressed at the highest density in the
astrointestinal tract.33,34 Thus, it is likely that the gastroin-
estinal effects mediated by this receptor are achieved at
ow dosages of octreotide, explaining the similar efﬁcacy of
he two dosages used in our study.
Adverse effects occurred in 2 patients (12.5%) who were
reated with the highest dose of the drug. However, we
ound no statistical association between dosage and adverse
ffects, although this may be due to the small number of
atients with this outcome.
It can be concluded, based on our study, that octreotide
AR is an effective therapy for prophylaxis of gastrointesti-
al bleeding resulting from angiodysplasia, by decreasing
ransfusion requirements and the need for hospitalization
or gastrointestinal bleeding. Patients with aortic stenosis
eneﬁted most from the therapy.
There was no increase in efﬁciency when higher doses of
he drug were used, therefore we recommend lower dosages
10mg/month) to avoid excess expense and lower the inci-
ence of potential adverse effects.
Our series, despite being the largest reported to date,
ave some limitations; it is a retrospective cohort study with
small number of patients (n = 16) and lacks a control group.
rospective, double blind and randomized studies are warr-
nted to validate the efﬁcacy and safety of this therapy for
his indication.
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